Urological Malignancies Programme welcomes new co-lead Dr Brent O'Carrigan
From 1st February 2023, Dr Brent O'Carrigan joins Professor Grant Stewart as co-lead for the UM Programme. Brent replaces Dr Sarah Welsh, who retired from medicine in January, as the medical oncology lead for the programme.
Dr O'Carrigan is a consultant medical oncologist specialising in kidney cancer and melanoma at Addenbrooke’s Hospital, Cambridge. He trained in Sydney and London, completing a fellowship in early phase cancer trials at the Royal Marsden Hospital and PhD in translational cancer research in immuno-oncology at the University of Cambridge, awarded both a Sir John Monash Foundation and Cambridge Trust International Scholarship.
He is principal investigator for a broad portfolio of academic and commercial clinical trials in both kidney cancer and melanoma, including cellular therapy trials. He is Clinical Cancer Lead for the NHS Genomics Laboratory Hub (GLH) for the East of England and East Midlands and member of NHS England's National Genomic Test Directory working group. He is deputy chair of the NCRI Skin Group and develops the national strategy for academic research into skin cancer across the UK. Regionally, he chairs the immunotherapy toxicity working group and is deputy chair of the outpatient clinic management group. He serves on a number of national trial management groups and data safety and monitoring boards. He was awarded the Royal Australian College of Physicians medal in 2012 for the highest mark in the national specialist examinations across Australia and New Zealand.
Outside of professional life, Brent is a Dad to three young children, keen cyclist (and swimmer when time permits) with a passion for international travel off the beaten track.